Prostate Cancer - Results from #28660

Study of investigational agent abiraterone acetate for metastatic advanced prostate cancer unblinded after meeting pre-determined criteria September 10, 2010

Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics - Abstract May 31, 2010

Abiraterone acetate: A promising drug for the treatment of castration-resistant prostate cancer - Abstract May 27, 2010

Abiraterone acetate: A promising drug for the treatment of castration-resistant prostate cancer - Abstract May 27, 2010

5A prospective survey of current prostate biopsy practices among oncological urologists - Abstract April 29, 2010

Management of Urological Cancers During Pregnancy April 7, 2010

Editorial - Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer March 30, 2010

Abiraterone acetate for castration resistant prostate cancer - Abstract March 29, 2010

GU Cancers Symposium 2010: ASCO ASTRO SUO - Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC) - March 9, 2010

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy - Abstract March 2, 2010

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with Docetaxel-treated castration-resistant prostate cancer - Abstract March 1, 2010

Significant and sustained antitumor activity in post-Docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate - Abstract March 1, 2010

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer - Abstract February 8, 2010

Does every prostate cancer need active intervention? - Multimedia Presentation October 29, 2009

A feasibility study of novel ultrasonic tissue characterization for prostate-cancer diagnosis: 2D spectrum analysis of in vivo data with histology as gold standard - Abstract October 12, 2009

ASCO 2009 - Phase II Multicenter Study of Chemotherapy-Naive Castration-Resistant Prostate Cancer (CRPC) not Exposed to Ketoconazole, Treated with Abiraterone Acetate (AA) Plus Prednisone - Session Highlights June 1, 2009

ASCO 2009 - A Multicenter Phase II Study of Abiraterone Acetate (AA) in Docetaxel Pretreated Castration-Resistant Prostate Cancer (CRPC) Patients - Session Highlights June 1, 2009

ASCO 2009 - Circulating Tumor Cells (CTC) in Patients with Metastatic Castration-Resistant Prostate Cancer (CRPC) Receiving Abiraterone Acetate (AA) after Failure of Docetaxel-Based Chemotherapy - Session Highlights June 1, 2009

Working patterns and perceived contribution of prostate cancer clinical nurse specialists: A mixed method investigation - Abstract April 20, 2009

The Efficacy and Safety of Degarelix: A 12-Month, Comparative, Randomized, Open-Label, Parallel-Group Phase III Study in Patients with Prostate Cancer - Abstract December 12, 2008

Page 1434 of 1435